Search

Displaying results 2921 - 2930 of 8974 in total
  1. Drug

    Diosmin

    go.drugbank.com/drugs/DB08995
    ApprovedInvestigational

    Compression and pharmacotherapy are frequently used to manage chronic venous insufficiency, improving circulation and symptoms of venous disease. … It is used for the improvement of capillary fragility or venous insufficiency, including chronic venous insufficiency (CVI) and hemorrhoids.

    Synonyms: Diosmetin 7-O-rutinoside
  2. Drug

    Proline

    go.drugbank.com/drugs/DB00172
    ApprovedInvestigationalNutraceutical

    It is an essential component of collagen and is important for proper functioning of joints and tendons.

    Mixtures: GLAMIN SOLUTION FOR INFUSION, KABIVEN EMULSION FOR INFUSION
  3. Indication

    Asthma

    go.drugbank.com/conditions/DBCOND0013565
    Drugs: Albuterol · Ambrosia artemisiifolia pollen · Aminophylline · Arformoterol · Beclomethasone dipropionate · Budesonide +39 more
    Synonyms: Asthma due to internal immunological process
  4. Drug

    Xenon Xe-129

    go.drugbank.com/drugs/DB17386
    ApprovedInvestigational

    [Helium-3] (He-3) is the one most commonly used due to its strong signal and favorable safety profile, but its use in other applications has affected its availability. … [A255183] In December 2022, the FDA approved the use of hyperpolarized Xe-129 for use with MRI for the evaluation of lung ventilation.

  5. Drug

    Colchicine

    go.drugbank.com/drugs/DB01394
    ApprovedInvestigational

    Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus."[A183611] Its use was first approved by the FDA in 1961.

    Categories: Experimental Unapproved Treatments for COVID-19, Preparations With No Effect on Uric Acid Metabolism
  6. Drug

    mRNA-1345

    go.drugbank.com/drugs/DB18739
    ApprovedInvestigational

    [L53403,L52380] In June 2025, its US indication was expanded to include patients 18-59 years old at increased risk of disease. … mRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older.

  7. Drug

    Terfenadine

    go.drugbank.com/drugs/DB00342
    ApprovedWithdrawn

    In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.

    Categories: Antihistamines for Systemic Use
  8. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    Asthma is a heterogeneous chronic obstructive respiratory disease with both "type 2" (T2) and T2-low endotypes characterized by reduced airflow, chronic inflammation, and airway remodelling. … [A243769] Conversely, tezepelumab, which targets the upstream master regulator TSLP, has the potential to be effective across asthma endotypes.

    Categories: Drugs for Obstructive Airway Diseases
  9. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    [L2336] Opicapone is used for adjunct therapy to levodopa and carbidopa in adult patients with Parkinson's disease and end-of-dose motor fluctuations. … Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily [L2336] and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase

  10. Drug

    Famtozinameran

    go.drugbank.com/drugs/DB17088
    ApprovedInvestigational

    [L43922] It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.4/BA.5.[L43907,L43912]